Nifty
Sensex
:
:
11709.10
39086.21
-119.15 (-1.01%)
116.41 (0.30%)

Pharmaceuticals & Drugs

Rating :
71/99

BSE: 500302 | NSE: PEL

2228.40
-59.45 (-2.60%)
21-May-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2290.00
  •  2383.25
  •  2216.10
  •  2287.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1308047
  •  29148.52
  •  3307.95
  •  1794.90

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 44,261.38
  • 30.05
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 85,955.17
  • 1.12%
  • 1.42

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 49.70%
  • 1.24%
  • 11.05%
  • FII
  • DII
  • Others
  • 5.47%
  • 0.79%
  • 31.75%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.60
  • 18.75
  • 18.79

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.19
  • 52.02
  • 24.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 31.37
  • -
  • 89.58

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.11
  • 21.58
  • 28.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.45
  • 1.88
  • 2.31

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.11
  • 17.93
  • 16.08

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
3,679.67
2,991.06
23.02%
3,489.08
2,858.36
22.07%
3,144.10
2,535.86
23.99%
2,902.49
2,254.07
28.77%
Expenses
1,738.03
1,610.27
7.93%
1,461.80
1,410.98
3.60%
1,491.06
1,265.97
17.78%
1,375.82
1,192.26
15.40%
EBITDA
1,941.64
1,380.79
40.62%
2,027.28
1,447.38
40.07%
1,653.04
1,269.89
30.17%
1,526.67
1,061.81
43.78%
EBIDTM
52.77%
46.16%
58.10%
50.64%
52.58%
50.08%
52.60%
47.11%
Other Income
85.23
36.51
133.44%
102.80
63.79
61.15%
56.31
75.39
-25.31%
14.43
83.84
-82.79%
Interest
1,315.65
830.64
58.39%
1,168.83
749.72
55.90%
1,016.18
724.71
40.22%
909.08
673.23
35.03%
Depreciation
135.43
115.10
17.66%
132.57
109.99
20.53%
123.36
129.33
-4.62%
128.79
122.91
4.78%
PBT
562.40
471.56
19.26%
828.68
651.46
27.20%
569.81
491.24
15.99%
50.98
349.51
-85.41%
Tax
224.29
-3,380.01
-
293.04
211.79
38.36%
162.78
189.75
-14.21%
181.02
102.05
77.38%
PAT
338.11
3,851.57
-91.22%
535.64
439.67
21.83%
407.03
301.49
35.01%
-130.04
247.46
-
PATM
9.19%
128.77%
15.35%
15.38%
12.95%
11.89%
-4.48%
10.98%
EPS
24.77
218.80
-88.68%
32.93
28.24
16.61%
26.59
22.13
20.15%
-3.82
17.44
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
13,215.34
10,631.03
8,503.65
6,341.51
5,122.61
4,502.74
3,520.19
2,158.87
1,673.08
3,624.47
3,244.81
Net Sales Growth
24.21%
25.02%
34.10%
23.79%
13.77%
27.91%
63.06%
29.04%
-53.84%
11.70%
 
Cost Of Goods Sold
1,529.21
1,518.35
1,401.10
1,305.94
1,314.40
1,195.02
1,113.57
927.24
694.03
1,397.21
1,236.54
Gross Profit
11,686.13
9,112.68
7,102.55
5,035.57
3,808.21
3,307.72
2,406.62
1,231.63
979.05
2,227.26
2,008.27
GP Margin
88.43%
85.72%
83.52%
79.41%
74.34%
73.46%
68.37%
57.05%
58.52%
61.45%
61.89%
Total Expenditure
6,066.71
5,475.73
5,004.50
4,649.26
4,237.69
3,867.83
3,105.38
2,159.80
2,465.72
2,944.25
2,699.75
Power & Fuel Cost
-
106.48
101.03
98.73
92.15
89.35
82.12
65.82
59.82
79.26
81.07
% Of Sales
-
1.00%
1.19%
1.56%
1.80%
1.98%
2.33%
3.05%
3.58%
2.19%
2.50%
Employee Cost
-
1,988.14
1,793.87
1,683.05
1,294.76
1,136.95
796.53
436.42
411.65
573.32
488.37
% Of Sales
-
18.70%
21.10%
26.54%
25.28%
25.25%
22.63%
20.22%
24.60%
15.82%
15.05%
Manufacturing Exp.
-
552.87
506.60
514.80
583.17
557.39
520.26
317.34
145.94
186.33
210.20
% Of Sales
-
5.20%
5.96%
8.12%
11.38%
12.38%
14.78%
14.70%
8.72%
5.14%
6.48%
General & Admin Exp.
-
648.69
628.30
567.54
524.38
473.46
306.39
201.10
202.80
300.12
274.64
% Of Sales
-
6.10%
7.39%
8.95%
10.24%
10.51%
8.70%
9.32%
12.12%
8.28%
8.46%
Selling & Distn. Exp.
-
265.52
280.64
205.77
269.81
245.82
194.24
121.27
110.50
250.27
202.98
% Of Sales
-
2.50%
3.30%
3.24%
5.27%
5.46%
5.52%
5.62%
6.60%
6.91%
6.26%
Miscellaneous Exp.
-
395.68
292.96
273.43
159.02
169.84
92.27
90.61
840.98
157.74
202.98
% Of Sales
-
3.72%
3.45%
4.31%
3.10%
3.77%
2.62%
4.20%
50.27%
4.35%
6.35%
EBITDA
7,148.63
5,155.30
3,499.15
1,692.25
884.92
634.91
414.81
-0.93
-792.64
680.22
545.06
EBITDA Margin
54.09%
48.49%
41.15%
26.69%
17.27%
14.10%
11.78%
-0.04%
-47.38%
18.77%
16.80%
Other Income
258.77
264.10
233.75
251.66
254.75
225.43
196.17
472.23
1,317.52
152.92
158.27
Interest
4,409.74
2,978.30
2,030.98
974.08
510.60
1,049.58
575.01
215.46
88.83
183.81
198.40
Depreciation
520.15
477.33
381.70
255.45
289.87
246.90
209.56
129.29
95.86
142.65
119.57
PBT
2,011.87
1,963.77
1,320.22
714.38
339.20
-436.14
-173.59
126.55
340.19
506.68
385.36
Tax
861.13
-2,876.42
228.12
49.51
344.96
62.75
24.76
5.63
3,679.71
18.03
21.94
Tax Rate
42.80%
-146.47%
17.41%
6.51%
11.36%
-14.43%
-12.85%
4.66%
22.22%
3.61%
6.44%
PAT
1,150.74
4,841.40
1,082.43
710.53
2,690.68
-498.28
-223.06
111.50
12,883.36
481.90
316.25
PAT before Minority Interest
1,153.71
4,840.19
1,082.14
710.53
2,690.39
-497.52
-217.48
115.26
12,883.67
481.74
318.81
Minority Interest
2.97
1.21
0.29
0.00
0.29
-0.76
-5.58
-3.76
-0.31
0.16
-2.56
PAT Margin
8.71%
45.54%
12.73%
11.20%
52.53%
-11.07%
-6.34%
5.16%
770.04%
13.30%
9.75%
PAT Growth
-76.23%
347.27%
52.34%
-73.59%
-
-
-
-99.13%
2,573.45%
52.38%
 
Unadjusted EPS
80.47
281.76
72.27
52.43
165.20
-29.10
-13.20
6.60
572.20
21.00
15.10

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
26,445.39
14,882.57
12,948.35
11,735.93
9,321.06
10,723.56
11,242.03
11,836.42
1,684.89
1,317.07
Share Capital
36.05
34.51
34.51
34.51
34.51
34.51
34.51
33.58
41.80
41.80
Total Reserves
26,409.34
14,848.06
12,913.84
11,701.42
9,286.55
10,689.05
11,207.52
11,802.84
1,643.09
1,275.27
Non-Current Liabilities
25,355.41
18,775.97
11,759.51
7,817.04
6,709.95
1,598.43
1,180.37
1,155.32
1,351.74
1,411.63
Secured Loans
23,420.22
11,714.16
3,099.39
1,539.08
504.42
609.44
208.81
232.25
575.36
451.66
Unsecured Loans
800.39
2,781.53
4,374.61
2,248.40
2,175.18
551.60
439.41
424.30
719.60
887.42
Long Term Provisions
5,144.43
4,689.03
4,497.72
4,048.77
4,026.55
346.63
346.81
258.89
0.00
0.00
Current Liabilities
22,478.73
18,962.28
10,542.27
5,694.05
9,490.09
11,764.78
6,111.55
4,693.23
1,041.96
1,070.46
Trade Payables
874.29
764.29
702.56
509.57
485.11
539.18
412.97
339.97
442.50
423.67
Other Current Liabilities
6,037.87
5,563.12
2,706.14
1,400.84
1,369.74
1,223.68
764.05
407.35
116.61
207.00
Short Term Borrowings
14,665.88
12,079.48
6,828.93
2,829.32
6,400.74
6,018.77
1,014.45
69.32
0.00
0.00
Short Term Provisions
900.69
555.39
304.64
954.32
1,234.50
3,983.15
3,920.08
3,876.59
482.85
439.79
Total Liabilities
74,291.53
52,634.03
35,250.25
25,276.13
25,521.10
24,098.57
18,544.29
17,690.73
4,078.59
3,806.61
Net Block
10,725.53
9,972.70
7,525.28
7,065.23
6,191.00
5,709.41
1,827.78
1,443.72
1,977.35
1,946.44
Gross Block
11,782.37
10,552.42
7,779.80
8,876.19
7,671.41
6,889.36
2,489.08
1,903.21
2,753.68
2,605.90
Accumulated Depreciation
1,056.84
579.72
254.52
1,810.96
1,480.41
1,179.95
661.30
459.49
776.33
659.46
Non Current Assets
61,725.87
43,470.62
30,595.31
19,911.89
21,149.44
16,397.63
13,307.38
8,036.06
2,145.56
2,066.92
Capital Work in Progress
647.18
879.63
355.02
277.14
491.07
371.96
260.77
138.45
135.66
92.65
Non Current Investment
23,526.62
21,716.66
15,682.30
6,820.88
9,249.93
6,969.82
6,577.86
380.86
32.55
27.83
Long Term Loans & Adv.
26,794.43
10,865.75
6,937.04
5,469.79
5,000.80
1,109.37
441.64
269.44
0.00
0.00
Other Non Current Assets
32.11
35.88
95.67
278.85
216.64
2,237.07
4,199.33
5,803.59
0.00
0.00
Current Assets
12,565.66
9,163.41
4,654.94
5,364.24
4,371.66
7,700.94
5,236.91
9,654.67
1,933.03
1,739.69
Current Investments
5,198.53
3,463.95
634.40
947.01
195.85
906.94
386.22
1,100.72
0.00
0.00
Inventories
774.02
723.07
723.77
674.94
652.30
541.82
465.60
382.56
469.45
483.36
Sundry Debtors
1,355.45
1,107.74
970.81
831.73
719.77
597.57
436.65
374.74
437.61
486.63
Cash & Bank
2,467.01
1,540.90
365.94
460.08
333.60
287.52
57.82
1,770.26
41.18
94.55
Other Current Assets
2,770.65
250.69
155.37
75.63
2,470.14
5,367.09
3,890.62
6,026.39
984.79
675.15
Short Term Loans & Adv.
2,518.77
2,077.06
1,804.65
2,374.85
1,636.43
4,048.46
3,785.30
4,114.27
976.93
665.13
Net Current Assets
-9,913.07
-9,798.87
-5,887.33
-329.81
-5,118.43
-4,063.84
-874.64
4,961.44
891.07
669.23
Total Assets
74,291.53
52,634.03
35,250.25
25,276.13
25,521.10
24,098.57
18,544.29
17,690.73
4,078.59
3,806.61

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
-15,966.59
-10,056.65
-6,956.19
-2,206.85
-1,604.43
-1,570.46
-684.78
-4,537.14
432.92
372.77
PBT
1,963.77
1,310.26
714.38
339.20
-436.14
-173.59
120.89
16,414.55
499.77
340.75
Adjustment
1,285.23
812.70
679.55
342.03
1,092.38
632.39
-140.32
-16,451.69
279.28
248.30
Changes in Working Capital
-18,374.37
-11,723.56
-7,977.81
-2,495.18
-2,132.96
-1,880.13
-585.24
-314.67
-231.56
-85.31
Cash after chg. in Working capital
-15,125.37
-9,600.60
-6,583.88
-1,813.95
-1,476.72
-1,421.33
-604.67
-351.81
547.49
503.74
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-841.22
-456.05
-329.63
-344.27
-125.70
-130.00
-74.45
-3,540.60
-107.66
-86.36
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
-42.68
-48.63
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,767.73
-2,402.84
-604.04
6,177.07
1,482.91
-1,664.46
-1,581.80
9,157.64
-157.46
-377.12
Net Fixed Assets
-350.07
-713.28
387.94
4.99
-74.35
-89.52
-357.29
614.10
-146.67
-289.09
Net Investments
-6,456.37
779.61
-7,831.14
1,363.48
-1,963.06
-2,512.81
-5,527.04
-1,390.60
-62.67
-1.72
Others
5,038.71
-2,469.17
6,839.16
4,808.60
3,520.32
937.87
4,302.53
9,934.14
51.88
-86.31
Cash from Financing Activity
18,650.25
13,570.46
7,543.90
-3,864.63
125.84
3,280.68
640.17
-2,984.62
-313.57
-9.75
Net Cash Inflow / Outflow
915.93
1,110.97
-16.33
105.59
4.32
45.76
-1,626.41
1,635.88
-38.11
-14.10
Opening Cash & Equivalents
1,364.21
226.57
233.35
325.18
268.65
52.98
1,678.88
38.12
94.55
55.10
Closing Cash & Equivalent
2,300.64
1,364.21
226.57
447.01
325.18
268.65
52.98
1,678.88
41.18
94.55

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
1467.15
857.49
746.05
676.19
537.05
617.86
647.74
700.87
80.15
62.65
ROA
7.63%
2.46%
2.35%
10.59%
-2.01%
-1.02%
0.64%
118.37%
12.22%
9.84%
ROE
23.42%
7.78%
5.76%
25.55%
-4.96%
-1.98%
1.00%
190.57%
32.10%
26.46%
ROCE
8.53%
8.96%
7.19%
18.70%
3.30%
2.41%
2.60%
213.86%
24.26%
24.15%
Fixed Asset Turnover
0.95
0.93
0.77
0.62
0.62
0.76
0.99
0.72
1.37
1.54
Receivable days
42.25
44.38
51.55
54.96
53.08
53.19
67.98
88.00
45.82
51.38
Inventory Days
25.68
30.89
40.00
47.02
48.12
51.81
71.06
92.29
47.24
48.86
Payable days
60.32
59.62
53.66
46.87
53.98
57.39
67.88
92.24
58.77
60.19
Cash Conversion Cycle
7.62
15.66
37.89
55.11
47.22
47.60
71.16
88.05
34.29
40.05
Total Debt/Equity
1.67
2.05
1.26
0.62
1.02
0.72
0.18
0.06
0.77
1.02
Interest Cover
1.66
1.65
1.78
6.94
0.59
0.66
1.56
187.46
3.72
2.72

News Update:


  • Piramal Enterprises’ arm launches two new branches in Gujarat
    17th May 2019, 10:15 AM

    The company will provide its housing finance offerings namely home loans, loans against property

    Read More
  • Piramal Enterprises signs MoU with Canada Pension Plan Investment Board
    7th May 2019, 14:32 PM

    The MoU is to co-sponsor a renewable energy focused Infrastructure Investment Trust

    Read More
  • Piramal Enterprises reports 91% fall in Q4 consolidated net profit
    26th Apr 2019, 14:46 PM

    The company has reported a standalone net loss of Rs 62.20 crore for the quarter ended March 31, 2019

    Read More
  • Piramal Enterprises - Quarterly Results
    26th Apr 2019, 14:29 PM

    Read More
  • Piramal Enterprises gets 1st ranking in India from LACP for its FY2018 Annual Report
    19th Mar 2019, 15:34 PM

    The company has also won the Platinum Award (Rank 1st globally) in ‘Conglomerates’ category

    Read More
  • Piramal Enterprises’ partner launches generic cinacalcet hydrochloride tablets in US
    12th Mar 2019, 14:38 PM

    Piramal’s subsidiary, Piramal Healthcare has partnered with Slate Run with the goal of developing a non-infringing formulation of cinacalcet hydrochloride tablets

    Read More
  • Piramal Enterprises’ business unit launches MITIGO in US market
    12th Mar 2019, 09:44 AM

    MITIGO is an opioid agonist, for use in continuous microinfusion devices indicated only for intrathecal or epidural infusion

    Read More
  • CARE assigns ‘A1+’ rating to Piramal Enterprises’ NCDs
    8th Mar 2019, 10:22 AM

    The agency has assigned rating to the company’s NCDs worth Rs 500 crore

    Read More
  • Supreme Court exempts Piramal Enterprises’ Saridon from List of Banned FDCs
    21st Feb 2019, 14:05 PM

    In September 2018, PEL had been awarded a stay order from the Supreme Court on the ban, which allowed it to continue manufacturing, distribution and sale of the FDC

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.